---
document_datetime: 2025-12-02 05:20:52
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ritonavir-viatris.html
document_name: ritonavir-viatris.html
version: success
processing_time: 0.1274832
conversion_datetime: 2025-12-28 04:39:09.499192
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ritonavir Viatris (previously Ritonavir Mylan)

[RSS](/en/individual-human-medicine.xml/67013)

##### Authorised

This medicine is authorised for use in the European Union

ritonavir Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Ritonavir Viatris (previously Ritonavir Mylan)](#news-on)
- [More information on Ritonavir Mylan](#more-information-on-ritonavir-mylan-1509)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Ritonavir Mylan. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Ritonavir Mylan.

For practical information about using Ritonavir Mylan, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Ritonavir Mylan and what is it used for?

Ritonavir Mylan is used in combination with other medicines to treat patients over two years of age who are infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).

Ritonavir Mylan contains the active substance ritonavir and is a 'generic medicine'. This means that Ritonavir Mylan contains the same active substance and works in the same way as a 'reference medicine' already authorised in the European Union (EU) called Norvir.

## How is Ritonavir Mylan used?

Ritonavir Mylan can only be obtained with a prescription and treatment with Ritonavir Mylan should be given by a doctor who has experience in the treatment of HIV infection. It is available as tablets (100 mg) and should be taken with food.

Ritonavir Mylan can be used as a 'pharmacokinetic enhancer' (booster) to increase the blood levels of other antiviral medicines that belong to the same group as Ritonavir Mylan (protease inhibitors) including amprenavir, atazanavir, darunavir, fosamprenavir, lopinavir, saquinavir, and tipranavir. The usual dose of Ritonavir Mylan for adults is 100 or 200 mg, once or twice a day. The dose depends on which other protease inhibitor is being taken. For more information, see the package leaflet provided with the other medicine.

Ritonavir Mylan can also be used in larger doses for a direct antiviral effect on HIV. The recommended dose for adults (aged 18 years or over) is 600 mg twice a day. For younger patients, the recommended dose depends on the patient's height and weight. Treatment should start with a low dose that is gradually increased over the first 14 days of treatment.

## How does Ritonavir Mylan work?

As a 'booster', the active substance ritonavir slows the breakdown of other protease inhibitor antivirals. This increases the levels of these protease inhibitors in the blood and enhances their antiviral effect.

At higher antiviral doses, ritonavir is a 'protease inhibitor'. This means that it blocks a viral enzyme called protease, which is involved in the multiplication of HIV. When the enzyme is blocked, the virus can no longer multiply normally, slowing down its spread. Ritonavir Mylan, taken in combination with other antiviral medicines, reduces the amount of HIV in the blood and keeps it at a low level. Ritonavir Mylan does not cure HIV infection or AIDS, but it may hold off damage to the immune system and the development of infections and diseases associated with AIDS.

## How has Ritonavir Mylan been studied?

Studies on the benefits and risks of the active substance in the approved uses have already been carried out with the reference medicine, Norvir, and do not need to be repeated for Ritonavir Mylan.

As for every medicine, the company provided studies on the quality of Ritonavir Mylan. The company also carried out a study that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Ritonavir Mylan?

Because Ritonavir Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Ritonavir Mylan approved?

The European Medicines Agency concluded that, in accordance with EU requirements, Ritonavir Mylan has been shown to have comparable quality and to be bioequivalent to Norvir. Therefore, the Agency's view was that, as for Norvir, the benefit outweighs the identified risk. The Agency recommended that Ritonavir Mylan be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Ritonavir Mylan?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ritonavir Mylan have been included in the summary of product characteristics and the package leaflet.

## Other information about Ritonavir Mylan

The European Commission granted a marketing authorisation valid throughout the European Union for Ritonavir Mylan on 10 November 2017.

For more information about treatment with Ritonavir Mylan, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Ritonavir Mylan : EPAR - Summary for the public

Reference Number: EMA/621228/2017

English (EN) (92.32 KB - PDF)

**First published:** 20/11/2017

**Last updated:** 20/11/2017

[View](/en/documents/overview/ritonavir-mylan-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-567)

български (BG) (119.93 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

20/11/2017

[View](/bg/documents/overview/ritonavir-mylan-epar-summary-public_bg.pdf)

español (ES) (92.65 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

20/11/2017

[View](/es/documents/overview/ritonavir-mylan-epar-summary-public_es.pdf)

čeština (CS) (117.32 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

20/11/2017

[View](/cs/documents/overview/ritonavir-mylan-epar-summary-public_cs.pdf)

dansk (DA) (92.28 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

20/11/2017

[View](/da/documents/overview/ritonavir-mylan-epar-summary-public_da.pdf)

Deutsch (DE) (94.16 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

20/11/2017

[View](/de/documents/overview/ritonavir-mylan-epar-summary-public_de.pdf)

eesti keel (ET) (91.44 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

20/11/2017

[View](/et/documents/overview/ritonavir-mylan-epar-summary-public_et.pdf)

ελληνικά (EL) (120.66 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

20/11/2017

[View](/el/documents/overview/ritonavir-mylan-epar-summary-public_el.pdf)

français (FR) (93.78 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

20/11/2017

[View](/fr/documents/overview/ritonavir-mylan-epar-summary-public_fr.pdf)

hrvatski (HR) (111.99 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

20/11/2017

[View](/hr/documents/overview/ritonavir-mylan-epar-summary-public_hr.pdf)

italiano (IT) (91.84 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

20/11/2017

[View](/it/documents/overview/ritonavir-mylan-epar-summary-public_it.pdf)

latviešu valoda (LV) (112.86 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

20/11/2017

[View](/lv/documents/overview/ritonavir-mylan-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (115.44 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

20/11/2017

[View](/lt/documents/overview/ritonavir-mylan-epar-summary-public_lt.pdf)

magyar (HU) (113.97 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

20/11/2017

[View](/hu/documents/overview/ritonavir-mylan-epar-summary-public_hu.pdf)

Malti (MT) (118.39 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

20/11/2017

[View](/mt/documents/overview/ritonavir-mylan-epar-summary-public_mt.pdf)

Nederlands (NL) (93.13 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

20/11/2017

[View](/nl/documents/overview/ritonavir-mylan-epar-summary-public_nl.pdf)

polski (PL) (118.85 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

20/11/2017

[View](/pl/documents/overview/ritonavir-mylan-epar-summary-public_pl.pdf)

português (PT) (93.03 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

20/11/2017

[View](/pt/documents/overview/ritonavir-mylan-epar-summary-public_pt.pdf)

română (RO) (115.01 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

20/11/2017

[View](/ro/documents/overview/ritonavir-mylan-epar-summary-public_ro.pdf)

slovenčina (SK) (117.26 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

20/11/2017

[View](/sk/documents/overview/ritonavir-mylan-epar-summary-public_sk.pdf)

slovenščina (SL) (112.87 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

20/11/2017

[View](/sl/documents/overview/ritonavir-mylan-epar-summary-public_sl.pdf)

Suomi (FI) (92.17 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

20/11/2017

[View](/fi/documents/overview/ritonavir-mylan-epar-summary-public_fi.pdf)

svenska (SV) (92.31 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

20/11/2017

[View](/sv/documents/overview/ritonavir-mylan-epar-summary-public_sv.pdf)

Ritonavir Mylan : EPAR - Risk Management Plan summary

English (EN) (139.51 KB - PDF)

**First published:** 12/10/2022

[View](/en/documents/rmp-summary/ritonavir-mylan-epar-risk-management-plan-summary_en.pdf)

## Product information

Ritonavir Viatris : EPAR - Product Information

English (EN) (517.42 KB - PDF)

**First published:** 20/11/2017

**Last updated:** 08/07/2025

[View](/en/documents/product-information/ritonavir-viatris-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-990)

български (BG) (673.78 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

08/07/2025

[View](/bg/documents/product-information/ritonavir-viatris-epar-product-information_bg.pdf)

español (ES) (615.67 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

08/07/2025

[View](/es/documents/product-information/ritonavir-viatris-epar-product-information_es.pdf)

čeština (CS) (603.17 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

08/07/2025

[View](/cs/documents/product-information/ritonavir-viatris-epar-product-information_cs.pdf)

dansk (DA) (473.59 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

08/07/2025

[View](/da/documents/product-information/ritonavir-viatris-epar-product-information_da.pdf)

Deutsch (DE) (527.93 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

08/07/2025

[View](/de/documents/product-information/ritonavir-viatris-epar-product-information_de.pdf)

eesti keel (ET) (467.28 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

08/07/2025

[View](/et/documents/product-information/ritonavir-viatris-epar-product-information_et.pdf)

ελληνικά (EL) (491.18 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

08/07/2025

[View](/el/documents/product-information/ritonavir-viatris-epar-product-information_el.pdf)

français (FR) (645.29 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

08/07/2025

[View](/fr/documents/product-information/ritonavir-viatris-epar-product-information_fr.pdf)

hrvatski (HR) (699.18 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

08/07/2025

[View](/hr/documents/product-information/ritonavir-viatris-epar-product-information_hr.pdf)

íslenska (IS) (494.82 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

08/07/2025

[View](/is/documents/product-information/ritonavir-viatris-epar-product-information_is.pdf)

italiano (IT) (683.86 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

08/07/2025

[View](/it/documents/product-information/ritonavir-viatris-epar-product-information_it.pdf)

latviešu valoda (LV) (587.72 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

08/07/2025

[View](/lv/documents/product-information/ritonavir-viatris-epar-product-information_lv.pdf)

lietuvių kalba (LT) (716.22 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

08/07/2025

[View](/lt/documents/product-information/ritonavir-viatris-epar-product-information_lt.pdf)

magyar (HU) (788.08 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

08/07/2025

[View](/hu/documents/product-information/ritonavir-viatris-epar-product-information_hu.pdf)

Malti (MT) (896.93 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

08/07/2025

[View](/mt/documents/product-information/ritonavir-viatris-epar-product-information_mt.pdf)

Nederlands (NL) (638.83 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

08/07/2025

[View](/nl/documents/product-information/ritonavir-viatris-epar-product-information_nl.pdf)

norsk (NO) (454.41 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

08/07/2025

[View](/no/documents/product-information/ritonavir-viatris-epar-product-information_no.pdf)

polski (PL) (644.72 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

08/07/2025

[View](/pl/documents/product-information/ritonavir-viatris-epar-product-information_pl.pdf)

português (PT) (440.14 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

08/07/2025

[View](/pt/documents/product-information/ritonavir-viatris-epar-product-information_pt.pdf)

română (RO) (742.29 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

08/07/2025

[View](/ro/documents/product-information/ritonavir-viatris-epar-product-information_ro.pdf)

slovenčina (SK) (774.25 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

08/07/2025

[View](/sk/documents/product-information/ritonavir-viatris-epar-product-information_sk.pdf)

slovenščina (SL) (423.86 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

08/07/2025

[View](/sl/documents/product-information/ritonavir-viatris-epar-product-information_sl.pdf)

Suomi (FI) (666.2 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

08/07/2025

[View](/fi/documents/product-information/ritonavir-viatris-epar-product-information_fi.pdf)

svenska (SV) (389.67 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

08/07/2025

[View](/sv/documents/product-information/ritonavir-viatris-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000280244 07/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ritonavir Viatris : EPAR - All Authorised presentations

English (EN) (11.15 KB - PDF)

**First published:** 20/11/2017

**Last updated:** 10/09/2024

[View](/en/documents/all-authorised-presentations/ritonavir-viatris-epar-all-authorised-presentations_en.pdf)

[Other languages (22)](#file-language-dropdown-114)

български (BG) (56.16 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

10/09/2024

[View](/bg/documents/all-authorised-presentations/ritonavir-viatris-epar-all-authorised-presentations_bg.pdf)

español (ES) (34.67 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

10/09/2024

[View](/es/documents/all-authorised-presentations/ritonavir-viatris-epar-all-authorised-presentations_es.pdf)

čeština (CS) (51.8 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

10/09/2024

[View](/cs/documents/all-authorised-presentations/ritonavir-viatris-epar-all-authorised-presentations_cs.pdf)

Deutsch (DE) (11.37 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

10/09/2024

[View](/de/documents/all-authorised-presentations/ritonavir-viatris-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (12 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

10/09/2024

[View](/et/documents/all-authorised-presentations/ritonavir-viatris-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (54.96 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

10/09/2024

[View](/el/documents/all-authorised-presentations/ritonavir-viatris-epar-all-authorised-presentations_el.pdf)

français (FR) (12.86 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

10/09/2024

[View](/fr/documents/all-authorised-presentations/ritonavir-viatris-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (50.42 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

10/09/2024

[View](/hr/documents/all-authorised-presentations/ritonavir-viatris-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (20.76 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

10/09/2024

[View](/is/documents/all-authorised-presentations/ritonavir-viatris-epar-all-authorised-presentations_is.pdf)

italiano (IT) (11.6 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

10/09/2024

[View](/it/documents/all-authorised-presentations/ritonavir-viatris-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (51.73 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

10/09/2024

[View](/lv/documents/all-authorised-presentations/ritonavir-viatris-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (52.41 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

10/09/2024

[View](/lt/documents/all-authorised-presentations/ritonavir-viatris-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (69.3 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

10/09/2024

[View](/hu/documents/all-authorised-presentations/ritonavir-viatris-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (53.92 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

10/09/2024

[View](/mt/documents/all-authorised-presentations/ritonavir-viatris-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (11.63 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

10/09/2024

[View](/nl/documents/all-authorised-presentations/ritonavir-viatris-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (37.7 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

10/09/2024

[View](/no/documents/all-authorised-presentations/ritonavir-viatris-epar-all-authorised-presentations_no.pdf)

polski (PL) (28.45 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

10/09/2024

[View](/pl/documents/all-authorised-presentations/ritonavir-viatris-epar-all-authorised-presentations_pl.pdf)

português (PT) (12.37 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

10/09/2024

[View](/pt/documents/all-authorised-presentations/ritonavir-viatris-epar-all-authorised-presentations_pt.pdf)

română (RO) (51.18 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

10/09/2024

[View](/ro/documents/all-authorised-presentations/ritonavir-viatris-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (59.92 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

10/09/2024

[View](/sk/documents/all-authorised-presentations/ritonavir-viatris-epar-all-authorised-presentations_sk.pdf)

Suomi (FI) (11.7 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

10/09/2024

[View](/fi/documents/all-authorised-presentations/ritonavir-viatris-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (37.98 KB - PDF)

**First published:**

20/11/2017

**Last updated:**

10/09/2024

[View](/sv/documents/all-authorised-presentations/ritonavir-viatris-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Ritonavir Viatris (previously Ritonavir Mylan) Active substance ritonavir International non-proprietary name (INN) or common name ritonavir Therapeutic area (MeSH) HIV Infections Anatomical therapeutic chemical (ATC) code J05AE03

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV 1 infected patients (adults and children of 2 years of age and older).

## Authorisation details

EMA product number EMEA/H/C/004549

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Viatris Limited

Damastown Industrial Park Dublin 15 Ireland

Opinion adopted 14/09/2017 Marketing authorisation issued 09/11/2017 Revision 18

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Ritonavir Viatris : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (115.94 KB - PDF)

**First published:** 10/09/2024

**Last updated:** 08/07/2025

[View](/en/documents/procedural-steps-after/ritonavir-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Ritonavir Mylan : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (129.57 KB - PDF)

**First published:** 12/06/2018

**Last updated:** 10/01/2024

[View](/en/documents/procedural-steps-after/ritonavir-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Ritonavir Mylan : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/749789/2017

English (EN) (381.21 KB - PDF)

**First published:** 20/11/2017

**Last updated:** 20/11/2017

[View](/en/documents/assessment-report/ritonavir-mylan-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Ritonavir Mylan

Reference Number: EMA/CHMP/541227/2017

English (EN) (68.18 KB - PDF)

**First published:** 15/09/2017

**Last updated:** 15/09/2017

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-ritonavir-mylan_en.pdf)

#### News on Ritonavir Viatris (previously Ritonavir Mylan)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11 to 14 September 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-september-2017) 15/09/2017

#### More information on Ritonavir Mylan

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 08/07/2025

## Share this page

[Back to top](#main-content)